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The sympathetic nervous system has a major role in the brain-immune cross-talk, but
few information exist on the sympathoadrenergic regulation of innate immune system.
The aim of this review is to summarize available knowledge regarding the sympathetic
modulation of the innate immune response, providing a rational background for the
possible repurposing of adrenergic drugs as immunomodulating agents. The cells of
immune system express adrenoceptors (AR), which represent the target for noradrenaline
and adrenaline. In human neutrophils, adrenaline and noradrenaline inhibit migration,
CD11b/CD18 expression, and oxidative metabolism, possibly through β-AR, although
the role of α1- and α2-AR requires further investigation. Natural Killer express β-AR,
which are usually inhibitory. Monocytes express β-AR and their activation is usually
antiinflammatory. On murine Dentritic cells (DC), β-AR mediate sympathetic influence
on DC-T cells interactions. In human DC β2-AR may affect Th1/2 differentiation of
CD4+ T cells. In microglia and in astrocytes, β2-AR dysregulation may contribute
to neuroinflammation in autoimmune and neurodegenerative disease. In conclusion,
extensive evidence supports a critical role for adrenergic mechanisms in the regulation
of innate immunity, in peripheral tissues as well as in the CNS. Sympathoadrenergic
pathways in the innate immune system may represent novel antiinflammatory and
immunomodulating targets with significant therapeutic potential.
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Introduction
Physiology and Pharmacology of Adrenergic Pathways
Adrenaline (“near the kidney,” from Latin roots ad and renes; US: epinephrine, from the
Greek roots epi and nephros, i.e., “on the kidney”) belongs together with noradrenaline (the
prefix “nor” standing for nitrogen öhne radikal, indicating the absence of a methyl group) to
Abbreviations: DC, Dendritic cells; NK, Natural killer cells; γδ T lymphocytes, Gamma Delta T lymphocytes; AR,
Adrenoceptors; Th, T helper lymphocytes; LC, Locus coeruleus; cAMP, Cyclic adenosine monophosphate; CNS, Central
nervous system; ILC, Innate lymphoid cells; PRR, Pattern recognition receptors; PAMP, Pathogen-associated molecular
patterns; DAMP, Danger (or damage)-associated molecular patterns; TLR, Toll-like receptors; NLR, NOD-like receptors;
CLR, C-type lectin receptors; RLR, RIG-I-like receptors; ALR, AIM2-like receptors; FPR, Formyl peptide receptors; gC1qR,
gC1q receptor; SPLUNC1, Nasal epithelial clone 1; hBD, Human β-defensin; HNP, Human neutrophil peptide; MAO,
Monoamine oxidase; VMAT, Vesicular monoamine transporter; EPO, Eosinophil peroxidase; TNF, Tumor necrosis factor;
SCF, Stem cell factor; MIP, Macrophage inflammatory protein; LPS, Lipopolysaccharide; IL, Interleukine; IE, Immediate-
early; MMP,Matrix metalloproteinases; PKC, Protein kinase C;MHC,Major histocompatibility complex; PLC, Phospholipase
C; PKA, Protein kinase A; CpG-C ODN, Type-C CpG oligodeoxynucleotides; COX, Cyclooxygenase; THP-1, Human
microglia-like cells; MDSC, Myeloid-derived suppressor cells.
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catecholamines, a group of chemicals containing a catechol or
3,4-dihydroxyphenyl group and an amine function. The first
step in the synthesis of Noradrenaline is the transformation
of the aminoacid tyrosine in Levodopa through the enzyme
tyrosine hydroxilase that is the key rate-limiting enzyme
in the biosynthetic pathway of Noradrenaline.Levodopa is
decaborxlated into dopamine and finally noradrenaline is
synthesized from dopamine by dopamine β-hydroxylase
and is converted to adrenaline by phenylethanolamine N-
methyltransferase (Figure 1). Adrenaline was isolated as pure
crystalline base in 1900 by Jokichi Takamine in New Jersey
and was the first hormone to be isolated in a pure state, while
noradrenaline was proved in 1949 by Ulf von Euler in Stokholm
to be the main sympathomimetic neurotransmitter in humans.
Noradrenaline act as neurotransmitter in the central and
peripheral nervous systems. The sympathetic nervous system,
through its preganglionic fibers, stimulates chromaffin cells in
the adrenal glands to release into the bloodstream adrenaline
(∼80% in humans) and noradrenaline (∼20%). In the brain,
noradrenergic neurons are located mainly in the locus coeruleus
(LC), and their axons project to hippocampus, septum,
hypothalamus and thalamus, cortex and amygdala, to cerebellum,
as well as to spinal cord. Brain adrenergic pathways control
attention, arousal and vigilance, and regulate hunger and feeding
behavior. Some central nervous system (CNS) neurons, mainly
located in the medullary reticular formation, utilize adrenaline
as the main neurotransmitter, possibly contributing to the
modulation of eating behavior and to blood pressure regulation.
In the periphery, noradrenaline is the main transmitter
of sympathetic postganglionic fibers. Main direct effects of
noradrenaline and adrenaline on peripheral tissues include:
smooth muscle contraction in blood vessels supplying skin,
kidney, and mucous membranes, stimulation of exocrine glands,
smooth muscle relaxation in the gut wall, bronchi, and blood
vessels supplying skeletal muscle, increases of heart rate and
force of contraction, increased glycogenolysis in liver and
muscle, lipolysis in adipose tissue, thermogenesis in the brown
adipose tissue, modulation of the secretion of insulin and rennin
(Feldman et al., 1997).
Adrenergic Receptors
The effects of noradrenaline and adrenaline are mediated by 7-
transmembrane, G-protein coupled receptors called “adrenergic
receptors” or “adrenoceptors” (AR) and classified in three major
types—α1, α2, and β—each further divided into three subtypes,
which are widely expressed throughout the CNS and in virtually
all peripheral tissues (Ahlquist, 1948; Bylund et al., 1994).
The order of potency in the activation of these receptors by
physiological ligands is noradrenaline > adrenaline for the α1-
and α2-AR and adrenaline > noradrenaline for the β-AR.
Activation of α1-AR by adrenergic agonists induces the
stimulation of a Gq and consequent phospholipase C (PLC)
activation that promotes hydrolysis of phosphatidylinositol
bisphosphate producing inositol trisphosphate and
diacylglycerol. The results of this activation is the release of
Ca++ as second messenger from non-mitochondrial pools or
protein kinase C (PKC) and mediating intracellular release
FIGURE 1 | Biosynthetic pathway of the catecholamines noradrenaline
and adrenaline from the aminoacid tyrosine. The synthesizing enzymes
are shown to the right of each arrow, while enzyme cofactors are shown to the
left (reproduced from the Wikimedia Commons—http://commons.wikimedia.
org).
(Bylund et al., 1994). The α2-AR are considered inhibitory
receptors; their activation induces the stimulation of a Gi
resulting in adenylate cyclase inhibition and reduction of cyclic
adenosine monophosphate (Bylund et al., 1994). Presynaptic
autoreceptors mediating inhibition of neurotransmitter
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release are mainly α2-AR, while postsynaptic AR include
all subtypes.
β-AR are coupled to a stimulatory Gs that leads to activation
of adenylate cyclase and accumulation of the second messenger
cAMP. In some situations, the β3-AR, can be coupled to Gi as well
as to Gs (Gauthier et al., 1996). Receptors stimulation induces
the protein kinase A (PKA) activation and phosporilation
of L-type Ca++ channels and Ca++ entry (Guimarães and
Moura, 2001). The β1-AR is the most important receptor that
mediates cardiovascular responses to noradrenaline released
from sympathetic nerve terminals and to circulating adrenaline.
β2-AR are primarily localized on airway smooth muscle cells and
are known to be involved in bronchial muscle relaxation.
AR ligands are used as drug therapeutics in different
cardiovascular diseases such as hypertension, angina pectoris,
congestive heart failure, or other diseases affecting million
of individuals such as asthma, depression, benign prostatic
hypertrophy, and glaucoma, as well as in shock, premature
labor, opioid withdrawal, and as adjunct medications in general
anesthesia (Bylund et al., 1994; Perez et al.) 1. Agonists of β2-
AR are employed in therapy as first line-treatment of asthma
and chronic obstructive pulmonary disease. The β3-AR is known
to be located primarily on adipocytes (Harms et al., 1974), but
at present no ligands of this receptors subtype are employed
in therapy. The physiopharmacology of AR is summarized in
Table 1.
Adrenergic Regulation of the Immune Response:
an Overview
Together with the hypothalamic-pituitary-adrenal axis, the
sympathetic nervous system represents, the major pathway
involved in the cross-talk between the brain and the immune
system. Sympathoadrenergic fibers innervate both primary
(bone marrow and thymus) and secondary (spleen and lymph
nodes) lymphoid organs, where noradrenaline and adrenaline
are released from nerve varicosities and or diffuse from the
bloodstream to act on AR expressed on immune cells (Elenkov
et al., 2000; Straub, 2004; Marino and Cosentino, 2013).
The Innate Immune System
The innate immune system is usually considered as the first
line of defense against invading microorganisms, however its
contribution is increasingly emerging in several noninfectious
diseases, including atherosclerosis (Chávez-Sánchez et al.,
2014) and its ischemic complications (Courties et al.,
2014), inflammatory bowel disease (Levine and Segal, 2013),
systemic sclerosis (O’Reilly, 2014), multiple sclerosis, and other
demyelinating disease (Mayo et al., 2012), neurodegenerative
disease (Boutajangout and Wisniewski, 2013), and only as
example, obesity (Lumeng, 2013) and diabetes (Lee, 2014) or that
innate immunity play a role in tumor recognition (Marcus et al.,
2014) and as a barrier to organ transplantation (Farrar et al.,
1Adrenoceptors. Last modified on 13/06/2014. Accessed on 02/09/2014.,
IUPHAR database (IUPHAR-DB). Available online at: http://www.iuphar-db.org/
DATABASE/FamilyMenuForward?familyId=4.
2013), and even in psychiatric disorders (Jones and Thomsen,
2013).
The innate immune system consists of effector molecules such
as complement and antibacterial peptides as well as of effector
cells. Complement is a proteolytic cascade system comprising
around 35 different soluble and membrane-bound proteins,
which is crucial for defense from microbial infections and for
clearance of immune complexes and injured cells (Noris and
Remuzzi, 2013). Antibacterial peptides are cationic peptides
(i.e., with positive net charge) containing 15–45 aminoacid
residues, which are both potent antibiotics usually targeting
bacterial membranes as well as effective modulators of the
immune response (Boman, 2003). Innate immune cells include:
granulocytes (neutrophils, eosinophils, basophils, mast cells),
monocytes/macrophages, dendritic cells (DC), natural killer
(NK) cells, γδ T lymphocytes, as well as the recently described
innate lymphoid cells (ILC). Immune responses in the CNS are
mediated by resident microglia and astrocytes, which are innate
immune cells without direct counterparts in the periphery.
Noxious stimuli alert the innate immune system through
pattern recognition receptors (PRR), which can be activated by
both exogenous pathogen-associated molecular patterns (PAMP)
and endogenous danger (or damage)-associated molecular
patterns (DAMP). PRR includes families of toll-like receptors
(TLR, “toll” being the German word for “amazing” or “great”),
NOD-like receptors (NLR, NOD standing for nucleotide-
binding oligomerization domain), C-type lectin receptors (CLR,
including mannose receptors and asialoglycoprotein receptors),
RIG-I-like receptors (RLR, where RIG-I stands for retinoic acid-
inducible gene 1), and AIM2-like receptors (ALR, AIM-2 or
“absent in melanoma 2” being part of the inflammasome and
contributing to the defense against microbial DNA). Formyl
peptide receptors (FPR, binding N-formyl peptides derived
from the degradation of either bacterial, or host cells) and
scavenger receptors (binding oxidized or acetylated low-density
lipoprotein) could be also included among PRR (Kawai and
Akira, 2010; Saxena and Yeretssian, 2014).
Adrenergic Modulation of the Innate
Immune System
Several excellent reviews deal with the role of
sympathoadrenergic pathways in the communication between
the nervous system and the immune system (Elenkov et al.,
2000; Kohm and Sanders, 2001; Marino and Cosentino, 2013;
Kenney and Ganta, 2014). However, most information regards
adaptive immunity, and adrenergic regulation of the innate
immune response is a relatively recent issue (Elenkov et al., 2000;
Wrona, 2006; Flierl et al., 2008a; Marino and Cosentino, 2013).
We will hereafter revise the most recent literature concerning
humoral and cellular arms of the innate immune response, with
specific attention to data obtained in humans and to their clinical
implications.
Complement
Although AR-mediated modulation of complement-induced
innate immune response has been characterized at least in
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TABLE 1 | Classification of AR (Perez et al.).
Main transduction
mechanisms
Human tissue distribution Physiological functions Therapeutic drugs (indications)
α1A Gq/G11 (phospholipase C
stimulation, calcium channel)
Cerebral cortex, cerebellum,
heart, liver, predominant subtype
in prostate and urethra,
lymphocytes
Contraction of urethral smooth
muscle, contraction of skeletal
muscle resistance arteries,
contraction of human
subcutaneous arteries
Agonists: methoxamine, methylnoradrenaline,
midodrine, oxymetazoline, metaraminol,
phenylephrine (vasoconstriction and
mydriasis, used as vasopressors, nasal
decongestants, and eye exams)
Antagonists: alfuzosin, doxazosin,
phenoxybenzamine, phentolamine, prazosin,
tamsulosin, terazosin, trazodone
(hypertension, benign prostatic hyperplasia)
α1B Spleen and kidney, somatic
arteries and veins, endothelial
cells, lymphocytes, osteoblasts
Contraction of arteries and veins,
osteoblast proliferation
α1D Cerebral cortex, aorta, blood
vessels of prostate, human
bladder, lymphocytes
Contraction of arteries, ureteral
contraction
α2A Gi/Go (adenylate cyclase
inhibition, potassium channel,
calcium channel, phospholipase
A2 stimulation)
Brain > spleen > kidney > aorta
= lung = skeletal muscle > heart
= liver
Presynaptic inhibition of
noradrenaline release,
hypotension, sedation,
analgesia, hypothermia
Agonists: dexmedetomidine, medetomidine,
romifidine, clonidine, brimonidine,
detomidine, lofexidine, xylazine, tizanidine,
guanfacine, amitraz (antihypertensives,
sedatives and treatment of opiate
dependence and alcohol withdrawal
symptoms)
Antagonists: phentolamine, yohimbine,
idazoxan, atipamezole, trazodone, mianserin,
mirtazapine (aphrodisiac, antidepressants,
reversal of α2-AR agonist-induced sedation)
α2B Kidney >> liver > brain = lung =
heart = skeletal muscle (also
reported in aorta and spleen)
Vasoconstriction
α2C Brain = kidney (also reported in
spleen, aorta, heart, liver, lung,
skeletal muscle)
Presynaptic inhibition of
noradrenaline release
β1 Gs (adenylate cyclase
stimulation)
Brain, lung, spleen, heart, kidney,
liver, muscle
Increase of cardiac output (heart
rate, contractility, automaticity,
conduction), renin release from
juxtaglomerular cells, lipolysis in
adipose tissue
Agonists Dobutamine, isoprenaline,
noradrenaline (bradycardia, heart failure,
cardiogenic shock) Antagonists Metoprolol,
atenolol, bisoprolol, propranolol, timolol,
nebivolol (cardiac arrhythmia, congestive
heart failure, glaucoma, myocardial infarction,
migraine prophylaxis)
β2 Brain, lung, lymphocytes, skin,
liver, heart
Smooth muscle relaxation,
striated muscle tremor,
glycogenolysis, increased mass
and contraction speed, increase
of cardiac output, increase of
acqueous humor production in
eye, dilatation of arteries,
glycogenolysis and
gluconeogenesis in liver, insulin
secretion, broncodilation
Agonists: (short-acting) salbutamol
(albuterol), levosalbutamol (levalbuterol),
terbutaline, pirbuterol, procaterol,
metaproterenol, fenoterol, bitolterol mesylate,
ritodrine, isoprenaline, (long-acting)
salmeterol, formoterol, bambuterol,
clenbuterol, (ultra-long-acting) indacaterol
(asthma, other effects: vasodilation in muscle
and liver, relaxation of uterine muscle, and
release of insulin) Antagonists: butoxamine,
timolol, propranolol (glaucoma, heart attacks,
hypertension, migraine headache;
investigational: stage fright, post-traumatic
stress disorder)
β3 Adipose tissue, gall bladder >
small intestine > stomach,
prostate > left atrium > bladder
(also reported in brown adipose
tissue and endothelium of
coronary microarteries)
Lipolysis, thermogenesis,
relaxation of miometrium and
colonic smooth muscle cells,
vasodilatation of coronary
arteries, negative cardiac
inotropic effect
Agonists: amibegron (investigational:
antidepressant, anxiolytic), solabegron
(overactive bladder, irritable bowel syndrome)
Antagonists: SR 59230A
animal models (Flierl et al., 2008a), nearly no information is
available regarding any direct effect of adrenergic pathways on
complement activity.
In vitro, adrenaline and noradrenaline may enhance in
monocytes the synthesis of several complement components
(such as C2, C3, C4, C5, factor B, properdin, beta 1H, and
C3b inactivator), possibly through the activation of α1-AR
(Lappin andWhaley, 1982). Adrenaline has also been reported to
inhibit C5-convertase generation from C3-convertase stabilized
by nickel ions (Kozlov and Lebedeva, 1998), and to inhibit
the covalent binding of the nascent C4b fragment of the
human complement component to IgG (Kozlov et al., 2000),
however the physiological relevance of such effects was not
investigated. In COS-7 transfected cells, it was shown that
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gC1qR (i.e., gC1q receptor, gC1q binding protein, p32, p33), a
multifunctional cellular protein that interacts with components
of the complement, kinin, and coagulation cascades as well as
with select microbial pathogens, may bind with the carboxyl-
terminal cytoplasmic domain of the α1B-AR (Xu et al., 1999).
Early studies in rodents suggested that α-AR stimulation
might result in increased secretion with saliva of a potent
kallikrein-like anticomplementary factor (Wallace et al., 1976).
In rats evidence has also been provided that the β-AR agonist
isoprenaline reduces the clearance function of complement
receptors on Kupffer cells, an effect which is sensitive to β-AR
antagonism (Loegering and Commins, 1988), and that adrenaline
may affect complement activity, both acutely (reduction followed
by increase and then return to normal values in 2 h) and in the
long term (increase 24 h after administration and peak after 2–3
days), however the specific contribution of AR subtypes remains
to be established (Vasin and Kuznetsova, 1995). Nonetheless,
another study in rats reported no effect of adrenaline (infused
together with corticosterone and glucagon) on liver synthesis
of albumin, complement component C3, and alpha 1-acid
glycoprotein (Pedersen et al., 1989). Remarkably, it has been
recently shown that the complement anaphylatoxin C5a may
induce cell apoptosis in adrenal medulla following cecal ligation
and puncture-induced sepsis in rats, as well as apoptosis of
pheochromocytoma PC12 cells in vitro, resulting in impaired
production of noradrenaline and dopamine (Flierl et al., 2008b),
revealing a novel interaction between adrenergic pathways and
the complement system.
Complement proteins may also affect brain adrenergic
pathways. Indeed, early reports suggest that C5a might
activate α-AR in the hypothalamus, possibly explaining the
neuropsychiatric symptoms sometimes associated with immune
complex diseases affecting the CNS (Williams et al., 1985).
Actually, C5a in the hypothalamus may act presynaptically,
resulting in noradrenaline release through the activation of a
specific C5a/C5ai receptor (Schupf et al., 1989).
Antibacterial Peptides
Evidence regarding an interplay between adrenergic pathways
and antibacterial peptides is recent and still fragmentary,
nonetheless the few available information supports its relevance.
For instance, it has been reported that the β-AR agonists albuterol
and formoterol may increase the antimicrobial protein short
palate, lung, and nasal epithelial clone 1 (SPLUNC1) (but not
β-defensin-2/hBD-2) in normal and asthma airway epithelial
cells, resulting in reduced Mycoplasma pneumoniae infection,
and interleukin (IL)-13 attenuates such effects, decreasing
SPLUNC1 and β-AR expression (Gross et al., 2010). A β-
AR-dependent mechanism seems to be involved also in the
psychological stress-induced decline in both cathelicidin and
human β-defensin (hBD)-3 expression in the skin of mice.
The antimicrobial peptide catestatin increased after short-term
stress, but then began to decline with more sustained stress. In
cultured keratinocytes, glucocorticoids downregulated catestatin
expression, but β-AR blockade increased catestatin, as well as
cathelicidin and hBD3 (Martin-Ezquerra et al., 2011). Human
neutrophil peptides (HNP) 1–3 are expressed also in the synovial
lining and adjacent sublining area (but not in deeper layers of
synovial tissue) in both rheumatoid arthritis and osteoarthritis
subjects, and their expression is concentration-dependently
inhibited by noradrenaline (Riepl et al., 2010). Adrenergic agents
may therefore enhance or inhibit the expression of antibacterial
peptides, depending on the specific circumstances, however the
factors contributing to the specific effects have been not yet
clarified.
Antibacterial peptides may also affect the response of tissues
to adrenergic stimulation. Recently, it has been reported that α-
defensin-1/HNP1 has relaxing effects on adrenergic contractions
of rat detrusor muscles, possibly through NF-κB pathways (Lee
et al., 2011).
Finally, adrenaline and noradrenaline have been shown
to downregulate S. Typhimurium virulence gene expression,
increasing its sensitivity to the antimicrobial peptide LL-37
(Spencer et al., 2010).
Cells
Granulocytes
Granulocytes (also known as polymorphonuclear leukocytes) are
named after the presence of intracellular granules. Granulocytes
are currently divided into different types, based on their staining
characteristics: neutrophils (the most abundant, representing
40–80% of total leukocytes in normal conditions), eosinophils,
basophils, and mast cells. Neutrophils are the major cellular arm
of the innate immune system. They are phagocytic cells which
are recruited to sites of infection to kill pathogens, however it is
increasingly evident that they also play a key role in progression
of non-infectious disease as well as in conditions characterized
by chronic inflammation (Mócsai, 2013; Mayadas et al., 2014).
Eosinophils have a prominent role in allergic diseases and
inflammatory responses against helminthic parasites, and are
involved in diseases involving mucosal surfaces, (e.g., allergic
asthma, atopic dermatitis, and gastrointestinal disorders) (Kita,
2013).Basophils are similar to tissue-residentmast cells and their
main function is the protection against infections with parasites,
including ticks, and helminths (Karasuyama and Yamanishi,
2014). Finally,mast cells are tissue-resident granulocytes mainly
located at the interface with the external environment. They
contain granules rich in histamine and heparin, and their main
roles are in allergy, wound healing, defense against pathogens, as
well as in antitumor immunity (da Silva et al., 2014).
Adrenergic modulation of granulocytes has been examined
mainly in neutrophil, nonetheless available evidence suggests that
adrenergic agents may profoundly affect all granulocyte subtypes.
Neutrophils
The β-AR agonist isoprenaline inhibits the respiratory burst in
human neutrophils (Nielson, 1987), an effect which has been
confirmed in later studies and attributed to β2-AR (Brunskole
Hummel et al., 2013). IL-8 production however seems to be not
sensitive to adrenaline, which only slightly reduces the expression
of the adhesion molecules CD15, CD44, and CD54, and only at
very high concentrations (1mM) (Wahle et al., 2005). Recently
however the in vitro adhesion of neutrophils to endothelial cells
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was shown to be inhibited by adrenaline, an effect likely due to β-
AR activation (Trabold et al., 2010). Desensitization of β-ARmay
occur after activation of the neutrophil respiratory burst (Vago
et al., 1990), and neutrophils from elderly subjects may have
decreased β-AR responsiveness (Cotter and O’Malley, 1983).
Ligand binding studies suggest that on average 1700–2200 β-
AR are expressed on neutrophil membranes (Pohl et al., 1991;
Schwab et al., 1993), while excluding the existence of α2-AR
(Musgrave and Seifert, 1994). We have recently shown that
human neutrophils express mRNA for all α- (with the only
exception of α2B-) and β-AR, in the following order: β3 > β2 >
α1A > α1B ∼ α2A ∼ β1 = α1D = α2C and that exposure of cells to
IL-8, a potent proinflammatory CXC-chemokine that promotes
neutrophil chemotaxis and degranulation, increasesmRNA levels
of all AR, and that adrenaline, probably through the involvement
of β-AR, profoundly affects neutrophil function (Scanzano et al.,
2015).
Conditions reported to be associated with decreased β-
AR expression on circulating neutrophils include: essential
hypertension (Corradi et al., 1981), juvenile type I diabetes
mellitus (Schwab et al., 1993), as well as strenuous physical
exercise (Ratge et al., 1988; Fragala et al., 2011). Increased β-AR
expression has been reported in post-traumatic stress disorder
(Gurguis et al., 1999).
Circumstantial evidence suggests that neutrophils may also
synthesize and release catecholamines. Noradrenaline and
adrenaline (as well as dopamine and their major metabolites)
have been identified human neutrophils (Cosentino et al.,
1999), which may also contain some catecholamine-degrading
enzymes, such as monoamine oxidase (MAO), possibly of the B
type (Balsa et al., 1989). Indeed, the MAO inhibitor pargyline
may lead at least in vitro to increased catecholamine levels
in human neutrophils (Cosentino et al., 1999). Interestingly,
exposure of rodent cells to lipopolysaccharide (LPS) results in
catecholamine release together with induction of catecholamine-
generating and degrading enzymes, and blockade of α2-AR
or pharmacological inhibition of catecholamine synthesis may
suppress (while α2-AR agonism or inhibition of catecholamine-
degrading enzymes enhances) lung inflammation in rodent
models of acute lung injury. Adrenalectomized animals show
even enhanced catecholamine release from phagocytes as well as
enhanced expression of catecholamine-synthesizing enzymes in
these cells. Such results have been explained suggesting that in
rodent phagocytes noradrenaline and adrenaline possibly activate
NFκB resulting in enhanced release of tumor necrosis factor
(TNF)-α, IL-1β and IL-6, and in the subsequent amplification
of acute inflammation via α2-AR (Flierl et al., 2007, 2009). We
recently identified in human neutrophils the presence mRNA for
tyrosine hydroxylase, the rate-limiting enzyme in the synthesis
of catecholamines, as well as for the vesicular monoamine
transporter (VMAT) 2 (but not 1) (Scanzano et al., 2015).
Eosinophils
The role of adrenergic pathways in eosinophils has been
studied mainly in relation to their role in allergic diseases and
inflammation, with particular regard to the respiratory tract.
Several studies indeed deal with the effects on eosinophils exerted
by β2-AR agonists used as bronchodilators, however most of
those studies do not provide clear evidence that any effects are
actually due to AR-operated pathways (e.g., due to the absence
of experiments with AR antagonists). This is a relevant issue,
since many effects exerted by β2-AR agonists may actually occur
through β-AR-independent mechanisms (Tachibana et al., 2002).
Early studies in humans examined the response of circulating
eosinophils to noradrenaline, adrenaline, and emotional stress
(Humphreys and Raab, 1950). In healthy subjects, the fall in
circulating eosinophils following adrenaline injection, as well
as the rise induced by the administration of β-AR antagonists
is well characterized (Koch-Weser, 1968). Several decades later
however β-AR detected on eosinophils, as well as on mast cells,
macrophages, and neutrophils, were still considered of limited
functional importance, due to rapid tachyphylaxis (Barnes,
1993).
Binding and functional data support the existence in
eosinophils from patients with eosinophilia and from the
peritoneal cavity of guinea pigs of β-AR possibly of the
β2 subtype, coupled to adenylate cyclase, but apparently not
involved in oxidative metabolism or degranulation (Yukawa
et al., 1990). A few years later however another study showed
that β2-AR may inhibit stimulated leukotriene C4 secretion and
eosinophil peroxidase (EPO, an eosinophil granule basic protein)
release in purified human peripheral blood eosinophils (Munoz
et al., 1994). Further evidence for the functional relevance of β-
AR in eosinophils is provided by results obtained in a model of
airway inflammation induced in anesthetized rats by injecting
substance P or bradykinin intravenously, where activation of β2-
AR by the β2-AR agonist formoterol was shown to reduce the
amount of plasma leakage and also the number of neutrophils
and eosinophils that adhered to the vascular endothelium at
sites of inflammation, an effect which could be antagonized by
the β2-AR antagonist propranolol (Bowden Sulakvelidze and
McDonald, 1994). Finally, EPO has been shown to decrease β-
AR density on guinea pig lung membranes (Motojima et al.,
1992). No information is available regarding the existence and
the functional relevance on eosinophils of α-AR as well as of β1-
or β3-AR.
Basophils
Clonidine, an α2-AR agonist used as antihypertensive, reduced
stimulated secretion of histamine in human basophils, however
the effect was inhibited by histamine receptor H2 blockers and
not by α1-AR or α2-AR antagonists, thus a contribution of α2-AR
could be ruled out (Miadonna et al., 1989). Recently, the antigenic
activation of basophils isolated from the blood of atopic donors
was shown to be decreased by adrenaline, an effect which was
reduced by the β-AR antagonist propranolol (Mannaioni et al.,
2010).
Mast cells
Both ligand-binding studies and functional data suggest that IgE-
mediated histamine release from mast cells may be inhibited by
β-AR (Masini et al., 1982). Desensitization of β-AR on human
lung mast cells may occur after prolonged exposure to β-AR
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agonists like isoprenaline, an effect which is prevented by β-
AR antagonists (Chong et al., 1995). Pharmacological evidence
suggests that β-AR mediating inhibition of histamine release
from human lung mast cells as well as from mast cells cultured
from human peripheral blood are β2-AR (Chong et al., 2002;
Wang and Lau, 2006). The β2-AR are also responsible in mast
cells isolated from human intestinal mucosa for the inhibition
exerted by adrenaline, noradrenaline, and salbutamol on IgE
receptor-dependent release of histamine, lipid mediators, and
TNF-α, as well as on proliferation, migration and adhesion to
fibronectin and human endothelial cells (Gebhardt et al., 2005).
Stem cell factor (SCF), the key human mast cell growth factor
which primes mast cells for mediator release and markedly
increases in asthmatic airways, profoundly reduces β2-AR-
mediated inhibition of histamine release from human lung
mast cells, possibly through SCF-dependent phosphorylation of
Tyr350 on the β2-AR with immediate uncoupling of the receptor
followed by receptor internalization (Cruse et al., 2010). At
least one review exists about β2-AR in human lung mast cells,
including the influence of genetic polymorphisms in the β2-AR
gene (Kay and Peachell, 2005). A report also exists suggesting the
existence of α1-AR in mast cells (Schulze and Fu, 1996) while
recently Prey and coworkers shows that human mast cells are
positive for the staining for both β1-AR and β2-AR while were
negative for β3-AR (Prey et al., 2014).
Monocytes/macrophages
Between myeloid cells, monocyte/macrophages show different
phenotypes, homeostatic turnover and functions in different
tissues (Geissmann et al., 2010). Monocytes have long been
considered as a developmental intermediate between bone
marrow precursors and tissue macrophages. Monocytes and
macrophages, together with DC, constitute the mononuclear
phagocyte system which plays a key role maintaining tissue
integrity during development and its restoration after injury,
as well as the initiation and resolution of innate and adaptive
immunity. Originally defined as bone marrow-derived myeloid
cells circulating in the blood as monocytes and populating tissues
as macrophages in the steady state and during inflammation, they
have different phenotype, homeostatic turnover, and function in
different tissues (Geissmann et al., 2010). Monocytes carry out
specific effectors’ functions during inflammation (De Kleer et al.,
2014) and are usually classified in CD14++CCCD16- classical
human monocytes or intermediates CD14++CCCD16+ cells.
Monocytes are endowed with chemokine receptors and PRR
that modulate their migration from blood to tissues, where they
produce proinflammatory cytokines and phagocyte cells and
toxic molecules. Differentiation into DC or macrophages occurs
during inflammation, and possibly in the steady state, depending
on the inflammatory and PAMP/DAMP microenvironment
(Serbina et al., 2008; Auffray et al., 2009).
Macrophages are resident phagocytic cells contributing to
tissue homeostasis through clearance of apoptotic cells and
production of growth factors. Macrophages are equipped with a
broad range of pathogen recognition receptors that make them
efficient at phagocytosis and induce production of inflammatory
cytokines. Different subsets of macrophages occur in the various
tissues (including liver Kupffer cells, lung alveolar, splenic and
peritoneal macrophages, dermal macrophages). Microglial cells
are resident macrophages in the CNS. The specific origins
and functions of all these subsets however still await thorough
investigation (Yona et al., 2013). Macrophages are also major
players in major disease such as cardiovascular disease (Swirski
and Nahrendorf, 2013), cancer (Biswas and Mantovani, 2010),
diabetes (Cnop et al., 2005).
The expression of β-AR on human monocytes has been
documented by both ligand binding and flow cytometric studies,
which also suggested that their density may be affected by
physical exercise (Ratge et al., 1988; Fragala et al., 2011). Receptor
desensitization has been reported in human monocytes at least
in vitro after prolonged β2-AR stimulation, possibly through up-
regulation of cAMP phosphodiesterase activity (Manning et al.,
1996).
The functional consequences of β-AR activation on human
monocytes is usually antiinflammatory and immunosuppressive
and includes: inhibition of oxygen radicals production (Schopf
and Lemmel, 1983) upregulation of TNF receptors and inhibition
of TNF (Guirao et al., 1997), reduction of C. albicans
phagocytosis (Borda et al., 1998), inhibition of LPS-induced
macrophage inflammatory protein-1 α (MIP-1 α) (Li et al.,
2003), as well as of LPS-induced IL-18 and IL-12 production
(Mizuno et al., 2005). Thus, while noradrenaline and adrenaline
may have antiinflammatory effects on human monocytes,
reversal of their effects may result proinflammatory. As a
consequence, the use of β2-AR agonists has been suggested
to be possibly beneficial in the treatment of sepsis through
inhibiting LPS-elicited IL-18 (Mizuno et al., 2005), while recently
the β2-AR antagonist propranolol has been shown to reduce
circulating immunosuppressive M2b monocytes in severely
burned children, suggesting a role for this drug in severely
burned patients to reduce their susceptibility to opportunistic
infections (Kobayashi et al., 2011). Adrenergic modulation of
monocytes may also contribute to explain the increased risk
of viral infections following highly stressful events (e.g., herpes
simplex virus type-1 and varicella zoster virus), due to activation
of the sympathetic nervous system. For instance, catecholamines
directly stimulate the human cytomegalovirus immediate-early
(IE) enhancer/promoter in monocytic cells via β2-AR, possibly
leading to the development of an active human cytomegalovirus
infection in latently infected patients (Prösch et al., 2000).
Adrenergic pathways in human monocytes may nonetheless
result also in proinflammatory effects. Adrenaline may indeed
increase monocyte attachment to laminin as well as oxidized-
low density lipoprotein phagocytosis, two effects which both
may be proinflammatory and atherogenic (Sarigianni et al.,
2011). In particular, activation of β-AR have been shown,
under certain conditions (e.g., in unstimulated cells), to lead to
proinflammatory responses in monocytes, including: increased
production of IL-18 (Takahashi et al., 2003), upregulation
of IL-4-induced CD23 (low affinity IgE receptor/Fc epsilon
RII) expression (Mencia-Huerta et al., 1991), and potentiated
IgE/anti-IgE-induced production of IL-6 (Paul-Eugène et al.,
1992, 1994), IgE (Paul-Eugène et al., 1993), increased generation
of superoxide anion, nitric oxide, and TxB2 (Paul-Eugène et al.,
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1994). LPS- or IL-1-stimulated human monocytes exposed to β2-
AR agonists may produce more antiinflammatory IL-10 as well
as pro-inflammatory IL-8 (Kavelaars et al., 1997). Adrenaline
may upregulate the surface expression of L-selectin (Rainer et al.,
1999), and noradrenaline and adrenaline may increase matrix
metalloproteinases (MMP)-1 in both circulating monocytes and
monocyte-derived macrophages (Speidl et al., 2004). The β-AR
agonist isoprenaline may decrease the response to LPS but per
se result in increased phorbol ester-induced production of TNF-
α, IL-12, and nitric oxide (Szelenyi et al., 2006). Isoprenaline
may also increase LPS-induced production of IL-1β, possibly
through the activation of β1-AR, which were directly identified
by immunoblot techniques as well as by radioligand binding
studies in the monocytic cell line THP-1 (Grisanti et al., 2010).
Recently, β1-AR autoantibodies isolated from the sera of heart
failure patients were shown to cause (TNF-α) secretion from the
murine macrophage-like cell line RAW264.7 (Du et al., 2012).
Early pharmacological evidence suggested the occurrence
of α-AR in human monocytes enhancing the synthesis of
complement components (Lappin and Whaley, 1982). Culturing
human circulating monocytes with dexamethasone or the β2-
AR agonist terbutaline may indeed trigger the expression
of α1B- and α1D-AR mRNA (Rouppe van der Voort et al.,
1999). LPS may result in a similar effect, possibly through
the activation of ERK-2 (Rouppe van der Voort et al., 2000).
The proinflammatory cytokines TNF-α and IL-1β respectively
upregulate and reduce α1B- and α1D-AR mRNA in the human
THP-1 monocytic cell line (while IL-6 and IL-8 seem to be
ineffective) (Heijnen et al., 2002). Recently, on monocytes a
homogenous α1B-AR subtype population was identified, which
changed to a heterogeneous receptor subtype expression pattern
when differentiated to macrophages. The agonist phenylephrine
synergistically increased LPS-induced IL-1β production and this
effect was blocked in the presence of a selective α1-AR antagonist
as well as of inhibitors of PKC, suggesting the occurrence
on human monocytes of α1-AR mediating proinflammatory
responses (Grisanti et al., 2011). Differentiation of human
monocytes into macrophages may result, at least in vitro, in
loss of β-AR responsiveness despite a functional adenylyl cyclase
system (Baker and Fuller, 1995). Expression of β-AR on human
macrophages is actually regulated upon activation in a stimulus-
dependent manner, thus that changes in receptor number may
occur in different states of cell maturation and function (Radojcic
et al., 1991). Remarkably, as humanmonocytes adhere to surfaces
and begin differentiation into macrophages, they may lose their
surface β2-AR and hence become insensitive to the inhibitory
effects of β2-AR agonists on LPS-induced TNF-α production,
an observation which has been related to the lack of anti-
inflammatory effect of β2-AR agonists on alveolar macrophages
or in clinical asthma (Ezeamuzie et al., 2011). Activation of β2-
ARmay inhibit the production of TNF-α and of IL-6 and increase
the production of IL-10 in PMA-differentiated U937 human
macrophages (Izeboud et al., 1999), however care should be
exerted when using these cells to study the physiopharmacology
of β-AR in human monocytes/macrophages, since β2-AR,
which are the main subtype of β-AR expressed by these cells,
exhibit lower expression on undifferentiated (monocytes) than
in PMA-differentiated U937 (macrophages) (Izeboud et al.,
1999). Quite interestingly, it has been proposed that in severe
sepsis priming via gut-derived noradrenaline may contribute to
increased release in pro-inflammatory cytokines from Kupffer
cells, ultimately leading to organ dysfunction. Such an effect,
which has been tentatively defined “sympathetic excitotoxicity
in sepsis,” could be mediated α2-AR on Kupffer cells (Miksa
et al., 2005). Recently, in a porcine model of wound healing,
both macrophage infiltration and angiogenesis were initially
decreased, whereas dermal fibroblast function was impaired after
treatment with β2-AR agonists, suggesting the potential of these
drugs to improve skin scarring (Le Provost and Pullar, 2015).
Interestingly, human monocyte-derived macrophages of stressed
subjects displayed decreased superoxide anion-responses after
stress, in direct correlation with higher plasma noradrenaline,
and noradrenaline-treated cells showed reduced superoxide
anion-production, an effect blocked by prior incubation with the
α-AR antagonist phentolamine (Kuebler et al., 2013). Similarly,
evidence about a negative effect of stress was recently shown in
models of tumor in which increased levels of catecholamines
contributes to the recruitment of macrophages and to the
increased activation of these cells in the tumor environment
(Armaiz-Pena et al., 2015). In addition negative effects were
elucidated by the sympathetic activation on cancer progression.
For example, metastasis in breast cancer, in mouse, was more
pronounced after stress and this effects were mimicked by β2-AR
stimulation (Sloan et al., 2010).
Finally, it has been reported that, at least in vitro, α2-AR
stimulation of type A (macrophage-like) and B (fibroblast-
like) synoviocytes produced an increase and a decrease in
the respective cell number, probably through Gi-coupled PLC
activation and the resulting stimulation of the PKC betaII/MAP
kinase (Mishima et al., 2001), providing preliminary evidence
for a role of α2-AR regulating local innate immunity in synovial
tissues.
In summary, consistent evidence supports the occurrence of
β-AR on human monocytes/macrophages: β2-AR are usually
regarded as mainly antiinflammatory, although under certain
conditions they can result in proinflammatory effects, while
recent evidence suggests also the occurrence of β-AR (possibly
β1-AR)-mediated proinflammatory responses (Grisanti et al.,
2010). Alpha-AR can also occur upon appropriate stimulation
and may mediate both pro- and antiinflammatory responses, but
defining their functional role still requires careful investigation.
According to evidence obtained in rodent cells,
monocytes/macrophages may also produce and utilize
noradrenaline and adrenaline as local transmitters. Indeed,
Spengler et al. (1994) showed in mouse peritoneal macrophages
stimulated with LPS that the β-AR selective antagonist
propranolol increased (and the α2-AR selective antagonist
idazoxan decreased) TNF-α production. In the same study,
the presence of intracellular noradrenaline was also reported
and interpreted as an evidence supporting the existence of an
adrenergic autocrine loop, possibly even more pronounced
in macrophages obtained from rats with streptococcal-cell-
wall-induced arthritis (Chou et al., 1998). Further support to
the possibility that macrophages may produce endogenous
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catecholamines has been provided by Nguyen et al. (2011),
who showed that exposure of mice to cold temperature rapidly
promoted alternative activation of adipose tissue macrophages,
which secreted catecholamines to induce thermogenic gene
expression in brown adipose tissue and lipolysis in white adipose
tissue. Absence of alternatively activated macrophages impaired
metabolic adaptations to cold, whereas administration of IL-4
increased thermogenic gene expression, fatty acid mobilization,
and energy expenditure, all in a macrophage-dependent manner
(Nguyen et al., 2011). Finally, it should be mentioned that
MAO type A is expressed in human monocytes in particular
after incubation with IL-4, and upregulation of its expression
may contribute in switching naive monocytes into a resolving
phenotype, indirectly highlighting another potential role for
endogenous adrenergic pathways in these cells (Chaitidis et al.,
2004, 2005).
Dendritic Cells
DC are specialized antigen-processing and presenting cells, with
high phagocytic activity as immature cells and high cytokine
producing capacity as mature cells. DC circulate in blood and
migrate from tissues to lymphoid organs, regulating T cell
responses both in the steady-state and during infection (Mellman
and Steinman, 2001; De Kleer et al., 2014). Remarkably,
DC found in the epidermis are the Langerhans cells, which
derive from the bone marrow, under steady-state conditions
are maintained locally, but during skin inflammation may be
replaced by blood-borne progenitors (Merad et al., 2002).
Few information exists regarding adrenergic pathways
in human DC. In CD40-stimulated human DC, activation
of β2-AR increases intracellular cAMP and inhibits IL-12
production, resulting in inhibition of Th1 and promotion of Th2
differentiation (Panina-Bordignon et al., 1997). In human DC
obtained from cord blood CD34+ precursor cells, noradrenaline
acting through β2-AR and increased cAMP inhibits LPS-
stimulated production of IL-23, IL-12 p40, TNF-α, and IL-6
without affecting IL-10 (Goyarts et al., 2008). This response is
similar to that obtained in mouse skin DC (Maestroni, 2005,
2006), thus suggesting that noradrenaline may regulate human
skin DC function resulting in decreased Th1 differentiation of
CD4+ T cells. Indirect evidence for adrenergic regulation of
human DC comes also from a study showing in 18 professional
athletes a correlation between the increase of peripheral blood
DC after intensive physical activity and serum adrenaline and
noradenaline levels (as well as with the extent of heart rate
elevation during exercise) (Suchánek et al., 2010). Recently,
adrenaline was shown to inhibit migration of human DC
through β1-AR signaling through arrestin2-PI3K-MMP9/CCR7
(Yang et al., 2013) and that DC functions are strongly affected
by catecholamines (probably β2-AR mediated) that induces a
profound suppression of the production of proinflammatory
cytokines (Nijhuis et al., 2014).
Most of the information so far available regarding adrenergic
pathways in DC has been obtained in murine DC, where AR
mediate sympathetic nervous system influences on DC-T cells
interactions contributing to the shaping of the appropriate
adaptive immune response (reviewed by Maestroni, 2005, 2006).
Both α1- and β2-AR are expressed on murine DC: α1-AR
stimulate DC migration, which on the contrary is inhibited
by β2-AR. Noradrenaline decreases IL-12 and increases IL-
10 production in both skin and bone marrow-derived DC
stimulated with bacterial TLR agonists and, as a consequence,
DC-induced T helper (Th) 1 priming is impaired. Such
observations may explain how reduced noradrenaline activity in
the skin may promote contact sensitizers-induced Th1 responses
(Maestroni, 2004). Noradrenaline also activates β2-AR-mediated
cAMP-PKA pathways to enhance DC production of IL-33,
resulting in direct Th2 differentiation and possibly contributing
to the stress-related progression of Th2-associated disorders
(Yanagawa et al., 2011). Sympathoadrenergic modulation of
the skin innate and adaptive immune response occurring after
stimulation with TLR2 (but not TLR4) agonists may promote
a Th1 adaptive response possibly relevant to Th1-sustained
autoimmune inflammatory skin diseases (Manni and Maestroni,
2008). In agreement with these findings, the β2-AR agonists
salbutamol may bias DC preexposed to TLR-2 and NOD2
agonists toward increasing the Th17/Th1 cell ratio finally
resulting in an IL-17 immune response, which may be relevant
in defense against extracellular bacteria, in the pathogenesis of
inflammatory diseases and for the antitumor response (Manni
et al., 2011). Adrenaline however was also shown to lead bone
marrow-derived murine DC to generate a dominant Th2/Th17
phenotype, possibly through the activation of β2-AR (Kim
and Jones, 2010). Nonetheless, recently it was shown that β2-
AR agonist-exposed mature murine DC displayed a reduced
ability to cross-present protein antigens while retaining their
exogenous peptide presentation capability, an effect which could
be mediated through a nonclassical inhibitory G (Gαi/0) protein.
Inhibition of cross-presentation was neither due to reduced
costimulatory molecule expression nor antigen uptake, but
rather to impaired phagosomal antigen degradation. A crosstalk
between the TLR4 and β2-AR transduction pathways at the
NF-κB level was also described, and in vivo treatment with a
β2-AR agonist resulted in inhibition of antigen protein cross-
presentation to CD8+ T cells, however with preservation of
their exogenous major histocompatibility complex (MHC) class
I peptide presentation capability (Hervé et al., 2013).
Recently, pharmacological evidence was also provided for
the occurrence on murine DC of α2-AR, which may mediate
enhancement of antigen capture, possibly contributing to explain
immune enhancement following acute stress (Yanagawa et al.,
2010). Dexmedetomidine, a highly-selective α2-AR agonist, has
been recently shown to affect murine bone marrow-derived DC,
delaying the intracellular proteolytic degradation of ovalbumin,
decreasing the expression of the surface molecules I-A(b) and
CD86, and suppressing Th-cell proliferation. Dexmedetomidine
also suppressed DC migration, and vaccination of animals
with dexmedetomidine-treated DC significantly suppressed the
contact hypersensitivity reaction in vivo (Ueshima et al.,
2013).
AR-dependent modulation of DC may be relevant also to
cancer vaccine strategies. Botta and Maestroni (2008) found that
β2-AR antagonism along with TLR2 activation at the site of
intradermal cancer vaccination may either enhance the resulting
antitumor response or be tolerogenic in dependence of the
maturation state of the transferred DC. Manipulation of β2-AR
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expressed in the site of DC inoculation may thus profoundly
influence the efficacy of the subsequent antitumor response.
Natural Killer Cells
NK cells, like other innate immune cells, were described as
nonspecific in their interactions with tumors or virus-infected
cells, however it is now well-defined that they express a
repertoire of inhibitory receptors (some specific for MHC
class I, others binding non-MHC ligands) that regulate their
activation. NK cells also express activating receptors, and their
complex interplay with inhibitory receptors is a matter of intense
investigation. NK cells circulate through the blood, lymphatics
and tissues, patrolling the body for the presence of transformed or
pathogen-infected cells (Yokoyama, 2005; Lanier, 2008; Chijioke
and Münz, 2013).
Human NK cells express high levels of β-AR. The highest
number of β-AR was found in CD16+CD56+ NK cells, and it
was even increased after physical exercise (Maisel et al., 1990).
Noradrenaline and adrenaline decrease NK cell cytotoxicity
through the activation of β-AR (likely β2-AR) (Whalen and
Bankhurst, 1990; Takamoto et al., 1991), however adrenaline
may also stimulate NK cell cytotoxicity at lower (submicromolar-
picomolar) concentrations (Hellstrand et al., 1985). In vitro, β2-
AR activation on NK cells reduces cell adhesion to endothelial
cells (Benschop et al., 1994, 1997), and in human subjects
administration of both adrenaline and noradrenaline modulates
themigratory capacity of humanNK cells via spleen-independent
β2-AR mechanism (Schedlowski et al., 1996; Benschop et al.,
1997). Nonetheless, evidence for β-AR-dependent increase of NK
cytotoxicity has been obtained in rats treated with amphetamine
(Glac et al., 2006) and more recently it has been shown that
also repeated social disruption in mice “primes” NK cells in
the spleen and lung to be more proficient in their cytolytic
and anti-viral/tumor effecter functions through β-AR activation
(Tarr et al., 2012). Also in light of such evidence, the possibility
that the previously reported β-AR- dependent decreased NK
cells function may arise from methodological issues has been
the subject of an interesting commentary (Ben-Eliyahu, 2012).
Nonetheless, a recent in vitro study which screened 1200 in-use
or previously approved drugs for their biological effect on freshly
isolated human peripheral blood-derived NK cells included β2-
AR agonists among the confirmed inhibitors (Theorell et al.,
2014) and that in general acute administration of catecholamines
(mimicking a stress condition) in vivo, through the interaction
with β-AR, suppress NK activity (Rosenne et al., 2014).
Human NK cells also express α-AR. In CD16+ lymphocytes,
β2-, α1-, α2-AR (but not β1-AR) were identified, and infusion
of adrenaline (but not noradrenaline) significantly decreased all
AR on NK cells (Jetschmann et al., 1997). Recently, rat NK cells
were shown to express both α1- and α2-AR. Activation of either
subtypes of α-AR augmented NK cytotoxicity, α1-AR possibly
signaling through PLC, while α2-AR effect through PKA (Xiao
et al., 2010).
Decreased NK activity induced by activation of β-AR is
presently considered among the main mechanisms responsible
for cancer progression associated with stressful conditions
resulting in activation of the sympathetic nervous system
(Shakhar and Ben-Eliyahu, 1998; Ben-Eliyahu et al., 2000; Page
and Ben-Eliyahu, 2000). Noradrenaline however may also inhibit
the generation of specific antitumor cytotoxic T lymphocytes
(Kalinichenko et al., 1999), and even chemical denervation may
lead to tumor growth (Brenner et al., 1992), thus suggesting a
complex role of the sympathetic nervous system in the regulation
of antitumor immunity.
In animal models, activation of the sympathoadrenergic
system through either stressful events or direct stimulation
of β-AR usually leads to compromised resistance to tumor
development and metastasis (Stefanski and Ben-Eliyahu, 1996;
Shakhar and Ben-Eliyahu, 1998). In a mouse model of restraint
stress, plasma adrenaline significantly rose immediately after
the release from restraint, while NK cells were decreased in
the lungs and blood but not in the spleen. Decreased number
of NK cells in the lungs and blood was reversed by the β-
AR antagonist propranolol, suggesting that acute stress reduces
the number of intraparenchymal lung NK cells via activation
of β-AR receptors (Kanemi et al., 2005). Impairment of NK
activity and reduced antitumor resistance due to stress and
β-AR stimulation is affected by age (Page and Ben-Eliyahu,
2000) and by gender (Page et al., 2008). Administration of
type-C CpG oligodeoxynucleotides (CpG-C ODN) was shown
to improve NK activity and immunocompetence, potentially
reducing metastatic dissemination after enhanced sympathetic
stress responses (Goldfarb et al., 2009), and it was proposed
to limit postoperative immunosuppression and metastatic
progression in association with pharmacological blockade of
β-AR and cyclooxygenase (COX) inhibition (Goldfarb et al.,
2011). Blockade of β-AR in association with COX inhibitors
have been recently proposed even in patients with hematological
malignancies, based on results obtained in animals and showing
that endogenous adrenaline together with prostaglandins may
mediate the promoting effects of stress on leukemia progression
through suppression of NK activity (Inbar et al., 2011).
Epidemiological studies support the hypothesis that exposure
to β2-AR antagonists may indeed reduce cancer progression and
mortality, e.g., in melanoma (De Giorgi et al., 2011) and in breast
cancer (Powe et al., 2010), although conflicting results have also
been reported (Shah et al., 2011; Choi et al., 2014). Whether such
effects are related to β-AR-induced suppression of NK antitumor
activity and/or to other effects of adrenaline and noradrenaline
on antitumor immunity and on tumor biology is still a matter of
debate. In any case, well-designed randomized clinical trials are
needed for several cancer types to establish the potential of AR
manipulation as antitumor therapy.
γδ T Lymphocytes
Gamma delta (γδ) T lymphocytes are unconventional T cells
that, like NK cells, functionally and phenotypically belong to
both the innate and the adaptive immune system and represent
a connection between the two. They represent about 1–10%
of circulating T cells (and even 50% at some mucosal sites),
and are involved in the defense against infectious diseases as
well as in the inhibition of tumor development and progression
(Carding and Egan, 2002). Recently, one study compared
lymphocytosis in response to an acute speech stress task, high
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and low intensity concentric exercise, and isoproterenol infusion
at two different doses, showing that γδ T lymphocytes were
mobilized in response to all three tasks in a dose-dependent
manner, and that their mobilization was greater than that of
CD8+ T lymphocytes and less than NK cells. The authors
suggest that mobilization of γδ T lymphocytes may provide
protection in the context of situations in which antigen exposure
is more likely to occur (Anane et al., 2009). Another study in
healthy subjects using infusion of adrenaline at physiological
concentrations confirmed such results, showing that γδ T
cells, together with CCR7−CD45RA+CD8+ effector T cells,
CD3+CD56+ NKT-like cells, CD16+CD56dim cytotoxic NK
cells, and CD14dimCD16+ proinflammatory monocytes, show
a rapid and transient increase after adrenaline. The proposed
mechanism is adrenaline-induced attenuation of cell attachment
to endothelium and subsequent demargination and release into
the circulation to provide immediate protection from invading
pathogens (Dimitrov et al., 2010).
Microglia
The first definition of the role of microglia in CNS was
provided by Pio del Rio-Hortega in 1932 who in the work
entitled “Cytology and cellular pathology of the nervous system”
described the role and effects of these cell population into
the brain (Del Rio-Hortega, 1932). In the CNS, microglia are
resident mononuclear phagocytes involved mainly in immune
responses and inflammatory diseases, which originate during
embryogenesis from the yolk sac and enter the CNS quite early
in the life of embryos. In a more recent paper, the complex
physiology of these cells was widely clarified (Kettenmann
et al., 2011) and in this review we can find informations about
the presence of A-DR and several other receptors. Microglial
cells play an important role in managing neuronal cell death,
neurogenesis, and synaptic interactions, and they contribute to
T-cell activation within the CNS (Katsumoto et al., 2014).
Adrenergic pathways have never been investigated in
human microglia, therefore available evidence so far regards
murine models. In murine microglia, by means of microarray
and immunohistochemistry, β2-AR and possibly β1-AR and
α2A-AR have been identified (Hertz et al., 2010). β-AR
activation increases the production of IL-1 β, TNF-α, and
IL-6 through cAMP and cAMP-dependent protein kinase
(Tomozawa et al., 1995) as well as ERK1/2 and P38 MAPK
(Wang et al., 2010). Nonetheless, noradrenaline acting on
β-AR may also induce IL-1ra and IL-1 type II receptor
expression in enriched cultures of murine microglia, thus
protecting cortical neurons against IL-1 β-induced neurotoxicity
(McNamee et al., 2010), and exposure to both β1- and β2-AR
agonists decreased TNF-α, IL-6 and monocyte chemoattractant
protein-1 production, prevented microglia activation, reduced
inflammation and exerted neuroprotective effects in LPS-
treated murine hippocampal slices (Markus et al., 2010).
Both noradrenaline and isoprenaline promote amyloid β
peptide uptake and degradation by murine microglial cells
through activation of β2-AR, thus providing a potential
link between central noradrenergic neurotransmission and
neuroinflammatory mechanisms in Alzheimer’s disease (Kong
et al., 2010). Preliminary evidence obtained in human microglia-
like (THP-1) cells seems to confirm the antiinflammatory and
neuroprotective role of noradrenaline in Alzheimer’s disease
pathology. In these cells, noradrenaline suppressed Aβ1-42-
mediated cytotoxicity andMCP-1 secretion, while enhancing Aβ-
mediated IL-1β secretion through action at β2-AR, and activation
of cAMP/PKA pathway and CREB (Yang et al., 2012). As regards
α-AR, no information exists with the exception of a recent study
in a rat model of monoarthritis, where it was shown that spinal
glia, as well as dorsal root ganglion primary afferent neurons,
express α2-AR and that the α2-AR agonist dexmedetomidine
exerted analgesic effects involving the blockade of spinal glial
activation (Xu et al., 2010).
Astrocytes
The term astroctyes includes at least two main categories of
cells that can be divided according to their morphology and
anatomical localization: protoplasmic cells and fibrous cells
(Sofroniew and Vinters, 2010). The first type are present in the
gray matter and were the first type of astrocytes identified by
means of silver impregnation. Fibrous astrocytes are localized
into the white matter and are quite different in the morphology.
At present we know that astrocytes are the most abundant
and heterogeneous neuroglial cells, their functions including
participating in the formation of the blood–brain barrier
and regulation of blood flow (by releasing several molecular
mediators such as prostaglandins, nitric oxide, and arachidonic
acid), maintaining the ion, pH, and transmitter homeostasis of
the synaptic interstitial fluid, sensing transmitter release at the
synaptic cleft and possibly releasing gliotransmitters, defending
the CNS from all types of insults and disease through reactive
gliosis. Astrocytes may also contribute to neuroinflammation
upon severe challenges by releasing pro-inflammatory molecules
(e.g., TNF-α, IL-1, IL-6) and possibly by contributing to antigen
presentation under autoimmune response, although this latter
function needs further investigation (Kimelberg and Nedergaard,
2010; Endo et al., 2015).
The main AR expressed by human astrocytes is the β2-AR,
which regulates glycogen metabolism, immune responses,
release of neurotrophic factors, as well as astrogliosis in
response to neuronal injury. Astrocytic β2-AR are potent
regulators of astrocytic TNF-α-activated genes, including
IL-6, CXCL2, CXCL3, VCAM1, and ICAM1 expression, and
in rats co-administration of the β2-AR agonist clenbuterol
and TNF-α skewed the T cell population toward a double
negative phenotype and induced a shift in the myeloid brain
cell population toward a neutrophilic predominance, suggesting
that astrocytic β2-AR and their downstream signaling pathway
may serve as potential targets to modulate neuroinflammatory
responses (Laureys et al., 2014). Nonetheless, β-AR stimulation
together with TNF-receptor triggering may also induce
synergistic IL-6 expression in astrocytes, which may contribute
to neurodegeneration and glioma development (Spooren
et al., 2011). Downregulation of the astrocytic β2-AR-pathway
has been proposed to contribute to several neurological
conditions such as multiple sclerosis, Alzheimer’s disease,
human immunodeficiency virus encephalitis, stroke, and hepatic
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encephalopathy (Laureys et al., 2010). In particular, regarding
multiple sclerosis, available evidence indicates that β2-AR are
decreased in astrocytes of patients, both in normal-appearing
white matter as well as in chronic active and inactive plaques (De
Keyser et al., 1999; Zeinstra et al., 2000), and it has been proposed
that in this disease astrocytes may serve as primary (facultative)
antigen-presenting cells due to a failure of β2-AR-mediated
suppression of MHC II molecules (De Keyser et al., 2003).
Astrocyte β2-AR dysregulation however may contribute to
pathogenesis and progression of multiple sclerosis also through
deficient inhibition of nitric oxide and proinflammatory cytokine
production and glutamate uptake, as well as through deficient
glycogenolysis and production of trophic factors (De Keyser
et al., 2004), and reduced perfusion of normal-appearing white
matter (De Keyser et al., 2008). Astrocytes as therapeutic targets
inmultiple sclerosis were challenged in a proof of concept clinical
study by use of fluoxetine, which activates PKA in astrocytes.
PKA is physiologically activated by β2-AR-mediated cAMP
increase and in turn suppresses coactivator class II transactivator,
which regulates MHC class II molecule transcription (De Keyser
et al., 2010). Direct activation of PKA could in principle bypass
the functional deficiency of astrocytes, however preliminary
results need to be confirmed and extended in larger, randomized
studies.
No information exists regarding α-AR, with the exception
of a study showing the occurrence of α1-AR in astrocytes from
human optic nerves (Mantyh et al., 1995). Interestingly, the
human U373 MG astrocytoma cell line express α1B-AR coupled
to phosphoinositide hydrolysis and calcium mobilization, which
mediate amitogenic response to α1-AR-agonists (Arias-Montaño
et al., 1999).
Conclusions and Perspectives
Although adrenergic pathways represent the main channel of
communication between the nervous system and the immune
system, their role has received more attention as regards
modulation of adaptive immunity (Elenkov et al., 2000;
Cosentino and Marino, 2013; Marino and Cosentino, 2013), in
comparison to innate immunity.
Consistent evidence however indicates that adrenergic
mechanisms play a significant role even in immune cells.
In particular, in human neutrophils migration, CD11b/CD18
expression, and oxidative metabolism are inhibited possibly
through β-AR, although a contribution by α1- and α2-AR cannot
be discarded. Inhibitory β-AR may occur also on NK cells, which
also express α-AR with undefined functional role. Monocytes
express β-AR which are usually antiinflammatory, even if in
certain conditions proinflammatory responses may arise. Murine
DC express β-AR which modulate DC-T cells interactions,
while in human DC β2-AR may affect Th1/2 differentiation of
CD4+ T cells. β2-AR dysregulation in microglia and astrocytes
may contribute to neuroinflammation in autoimmune and
neurodegenerative disease. As a whole, the main AR expressed on
innate immune cells are β (possibly β2)-AR, although α-AR may
occur on selected cell types and under specific conditions. Further
studies however are needed to define the functional significance
of α-AR-mediated influence on the innate immune response.
On these basis, evaluation of β-AR agonists as potential
antiinflammatory drugs is strongly warranted. Agonists of β2-AR
are currently used as bronchodilating agents in asthma, however
the relative contribution of any eventual immunomodulating
activity of these drugs to their overall therapeutic effects
remains to be established. In addition, their usefulness in
different inflammatory conditions such as atherosclerosis, where
neutrophils are emerging key players (Marino et al., 2015), should
be carefully considered. On the other side, β-AR antagonists
might enhance the innate immune response, and therefore
their usefulness could be evaluated e.g., in the potentiation
of antitumor immunity. The possible immune effects of α-AR
ligands require additional investigation.
Issues awaiting clarification include AR expression and
function in the various innate immune cells subtypes, as well as
their effects on the humoral innate immune system (complement,
antibacterial peptides). In particular, no information is yet
available on innate immune cells which have been recently
discovered and characterized, such as ILC (Spits et al., 2013)
and myeloid-derived suppressor cells (MDSC) (Gantt et al.,
2014).
Circumstantial evidence also suggests the opportunity to
apply a pharmacogenetic approach to better understand
adrenergic modulation of the immune response and in particular
of innate immunity. For instance, individuals who were
homozygous for β2-AR Arg16 had higher levels of specific
IgE to Ascaris lumbricoides, higher A. lumbricoides egg counts,
and larger wheal sizes following skin-prick testing with A.
lumbricoides allergen (Ramsay et al., 1999), and inhibition of IgE-
mediated release of histamine from human lung mast cells is
more resistant to desensitization when the β2-AR bears mutant
(gly16 and glu27) forms compared to wild-type (arg16 and gln27)
forms (Chong et al., 2000).
Nonetheless, the present knowledge about the adrenergic
modulation of innate immunity already supports relevant
therapeutic applications, such as the use of α2-AR antagonists
in acute lung injury (Flierl et al., 2007, 2009), as well as of β-
AR antagonists to reduce the risk of opportunistic infections in
severely burned patients (Kobayashi et al., 2011). Moreover, as
adrenergic pathways also provide a link between stressful events
and chronic inflammatory disease such as atherosclerosis (Heidt
et al., 2014), investigating neuroimmune adrenergic mechanisms
will likely provide several opportunities to repurpose the wide
array of sympathoadrenergic agents currently used in medical
therapy for various non-immune indications for novel and
previously unanticipated indications.
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